Literature DB >> 17055073

2'-C-methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus.

Nesya Goris1, Armando De Palma, Jean-François Toussaint, Ina Musch, Johan Neyts, Kris De Clercq.   

Abstract

We report on the potent and selective in vitro antiviral activity of 2'-C-methylcytidine (2'-C-MetCyt) against foot-and-mouth disease virus (FMDV). FMDV belongs to the Picornaviridae and has the potential to cause devastating epidemics in livestock. The 50% and 90% effective concentrations (EC50 and EC90) for inhibition of the FMDV-induced cytopathic effect (CPE) formation were 6.4+/-3.8 and 10.8+/-5.4 microM. Comparable EC50 values for inhibition of viral RNA synthesis were observed. Treatment of FMDV-infected BHK-21 cells with 77 microM 2'-C-MetCyt resulted in a (1.6-3.2)x10(3)-fold reduction of infectious virus yield. Time-of-drug addition experiments suggest that 2'-C-MetCyt interacts with viral replication at a time point that coincides with the onset of intracellular viral RNA synthesis. In contrast to emergency vaccination, a potent and selective antiviral agent may provide almost immediate (prophylactic/therapeutic) protection against infection and thus constitute an important alternative/supplementary option to contain outbreaks such as those caused by FMDV.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17055073     DOI: 10.1016/j.antiviral.2006.09.007

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  16 in total

1.  Ribavirin-resistant variants of foot-and-mouth disease virus: the effect of restricted quasispecies diversity on viral virulence.

Authors:  Jianxiong Zeng; Haiwei Wang; Xiaochun Xie; Chen Li; Guohui Zhou; Decheng Yang; Li Yu
Journal:  J Virol       Date:  2014-01-22       Impact factor: 5.103

Review 2.  Therapeutic and prevention strategies against human enterovirus 71 infection.

Authors:  Chee Choy Kok
Journal:  World J Virol       Date:  2015-05-12

3.  Discovery of novel ribonucleoside analogs with activity against human immunodeficiency virus type 1.

Authors:  Michael J Dapp; Laurent Bonnac; Steven E Patterson; Louis M Mansky
Journal:  J Virol       Date:  2013-10-23       Impact factor: 5.103

4.  Efficacy of 2'-C-methylcytidine against yellow fever virus in cell culture and in a hamster model.

Authors:  Justin G Julander; Ashok K Jha; Jung-Ae Choi; Kie-Hoon Jung; Donald F Smee; John D Morrey; Chung K Chu
Journal:  Antiviral Res       Date:  2010-03-20       Impact factor: 5.970

5.  Ribavirin as a curative and prophylactic agent against foot and mouth disease virus infection in C57BL/6 suckling and adult mice model.

Authors:  Patel Nikunjkumar; Ramasamy Periyasamy Tamil Selvan; Veerakyathappa Bhanuprakash
Journal:  Virusdisease       Date:  2021-10-20

6.  Inhibition of enterovirus 71 by adenosine analog NITD008.

Authors:  Cheng-Lin Deng; Huimin Yeo; Han-Qing Ye; Si-Qing Liu; Bao-Di Shang; Peng Gong; Sylvie Alonso; Pei-Yong Shi; Bo Zhang
Journal:  J Virol       Date:  2014-08-06       Impact factor: 5.103

7.  Novel antiviral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71.

Authors:  Tzu-Chun Chen; Hwan-You Chang; Pei-Fen Lin; Jyh-Haur Chern; John Tsu-An Hsu; Chu-Yi Chang; Shin-Ru Shih
Journal:  Antimicrob Agents Chemother       Date:  2009-05-04       Impact factor: 5.191

8.  Repeated exposure to 5D9, an inhibitor of 3D polymerase, effectively limits the replication of foot-and-mouth disease virus in host cells.

Authors:  Devendra K Rai; Elizabeth A Schafer; Kamalendra Singh; Mark A McIntosh; Stefan G Sarafianos; Elizabeth Rieder
Journal:  Antiviral Res       Date:  2013-04-08       Impact factor: 5.970

9.  Inhibitors of foot and mouth disease virus targeting a novel pocket of the RNA-dependent RNA polymerase.

Authors:  Ryan C Durk; Kamalendra Singh; Ceili A Cornelison; Devendra K Rai; Kayla B Matzek; Maxwell D Leslie; Elizabeth Schafer; Bruno Marchand; Adeyemi Adedeji; Eleftherios Michailidis; Christopher A Dorst; Jennifer Moran; Christie Pautler; Luis L Rodriguez; Mark A McIntosh; Elizabeth Rieder; Stefan G Sarafianos
Journal:  PLoS One       Date:  2010-12-21       Impact factor: 3.240

Review 10.  Strategies to develop antivirals against enterovirus 71.

Authors:  Rei-Lin Kuo; Shin-Ru Shih
Journal:  Virol J       Date:  2013-01-22       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.